Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities.

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ ...

S hares of Iovance Biotherapeutics (NASDAQ: IOVA) have collapsed by about 47% from the peak they reached shortly after the company's first drug earned approval this February. Unfortunately, one of ...

It's been a wild roller-coaster ride for Iovance Biotherapeutics (NASDAQ: IOVA). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since ...